FDA chief scientist Namandjé Bumpus has been named as principal deputy commissioner, replacing long-serving Janet Woodcock when she steps down early next year.
Janet Woodcock will bring a career at the FDA spanning almost four decades to a close next year, retiring from her current role as principal deputy commissioner of the reg
In another twist to the Aduhelm approval tale, FDA's Janet Woodcock has called for an independent investigation into the relationship between agency staffers and Biogen executives.
With the first patient set to receive Biogen's new Alzheimer's drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA's approva
Agency veteran Dr Janet Woodcock is the new interim FDA commissioner appointed by president Joe Biden to replace outgoing Trump appointee Stephen Hahn.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.